

Inflammation, Selectins and Venous Thrombosis


Thomas W. Wakefield MD
Professor Emeritus of Vascular Surgery
University of Michigan

National Institutes of Health (RO1 HL070766, PO1 HL089407, R01 HL095091, T32 HL076123, VITA I, II); University of Michigan, Upjohn, Genetics Institute, Wyeth, Archemix, Selexys, Glycomimetics

No Financial Disclosures

Virchow's Triad (1856)


Circulatory stasis



Hypercoagulability



Endothelial injury



• Flow Abnormalities Leading to EC of embolic molecules and interactions platelet/PBs and release of IL-1 β from Glycocalyx

Inflammatory Mechanisms

Venous Thrombogenesis as an Inflammatory Process

• Complement Activation

Rayes J, **Conclusions: Inflammation promotes initiation and propagation of venous thrombosis. Targeting immune system and inflammation could help prevent venous thrombosis.** *Covid-19 bleeding complications affects the same pathways* [Review and Bull-Dok 10.1182/blood.2023022522](#) blood Visual Abstract

Leukocyte accumulation promoting fibrin deposition is mediated *in vivo* by P-selectin on adherent platelets

Theresa Palabrica^{*†}, Roy Lobb[‡], Barbara C. Furie^{*}, Mark Aronovitz[†], Christopher Benjamin[‡], Yen-Ming Hsu[‡], Susan A. Sajer^{*} & Bruce Furie^{*}

* Center for Hemostasis and Thrombosis Research, Division of Hematology-Oncology and † Division of Cardiology, New England Medical Center and the Department of Medicine and Department of Biochemistry, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
‡ Biogen Inc. 14 Cambridge Center, Cambridge, Massachusetts 02142, USA

Palabrica T et al, Nature 359:848-851, 1992

Selectins


Selectins are glycoproteins found primarily on endothelial cells, leukocytes and platelets.

They are involved in trafficking of leukocytes in acute and chronic inflammatory processes, including:

- Post-ischemic inflammation in muscle, kidney and heart
- Skin inflammation
- Atherosclerosis
- Glomerulonephritis
- Lupus Erythematosus
- DVT

Diaz - Wakofield, FVC WITFENS, 2009, Chap 4, 13-22.

Rodent Ligation Model





NET formation from stimulated neutrophils from ^ΔCT mice (Elevated Circulating P-Selectin) was significantly increased, suggesting that **NET** formation may be enhanced in these mice

Etulain J, Martinod K, Wong SL, et al. *Blood* 126:242-246, 2015

P-selectin Inhibition Therapeutically Promotes Thrombus Resolution and Prevents Vein Wall Fibrosis Better than Enoxaparin and an Inhibitor to von Willebrand Factor


Diaz JA¹, Wroblewski SK¹, Pechota AR¹, Hawley AE¹, Roelofs KJ¹, Doornbos NK¹, Gabriel JE¹, Reynolds G¹, Farris DM¹, Shea EM¹, Lester PA¹, Lundy FJ², Lowe S², Henke PK³, Schaub RG³, Wakefield TW¹, Myers Jr. DD¹

Arterioscler Thromb Vasc Biol
Volume 35(4):829-837
March 25, 2015

¹Department of Surgery, Section of Vascular Surgery, Conrad Jobst Vascular Research Laboratories;
²Department of Radiology, University of Michigan, Ann Arbor, Michigan,
³NKT Therapeutics, Inc., Waltham Massachusetts, USA.



Thomas W. Wakefield – Denisa D. Wagner: NIH HL095091 (RFA)





 American Venous Forum
 26th Annual Meeting, New Orleans
 February 19 – 22, 2014.

Aptamers

Aptamers

- Aptamers are nucleic acid species that offer molecular recognition properties like antibodies. (Aptamers have been engineered through repeated rounds of *in vitro* selection named, SELEX [systematic evolution of ligands by exponential enrichment] to bind to various molecular targets).

Anti-P-selectin Aptamer, ARC5692	Anti-VWF Aptamer, ARC15105
<p>Selectivity</p> <ul style="list-style-type: none"> ○ Binds to soluble and bound P-selectin. 	<p>Selectivity</p> <ul style="list-style-type: none"> ○ Binds to VWF in circulation.
<p>Functional activity</p> <ul style="list-style-type: none"> ○ Blocks P-selectin/PSGL-1 interaction. 	<p>Functional activity</p> <ul style="list-style-type: none"> ○ Blocks VWF A1 domain/platelet glycoprotein Ib (GP Ia) interaction. 



E-Selectin

- E-Selectin is a glycoprotein expressed from activated endothelium that facilitates thrombosis, directly modulating neutrophil and monocyte activity
- We have identified E-selectin as an important regulator of thrombus formation and fibrin content in a mouse venous thrombosis model. (Myers D et al, J Surg Res 2002, Sullivan VV et al, J Surg Res 2003, Myers D et al, Thromb Haemost 2007)
- E-selectin has been shown to be efficient at raising the affinity and avidity of CD18 (MAC-1) integrins which support neutrophil trafficking to sites of acute inflammation and recruit platelets and red blood cells. (Chase SD et al, Ann Biomed Eng 2012)
- Patients homozygous for the *S128R* E-selectin allele have an increased risk for VTE recurrence, highlighting the importance of E-selectin in venous thrombosis. (Jilma B et al, Arch Intern Med 2006)

E-Selectin Inhibitor (GMI-1271) small molecule antagonist






Figure 1: Chemical formula of GMI-1271.



CTR vs, Tx 1271 10 mg/kg BID, *P=0.0271
 CTR vs, Tx 1271 20 mg/kg BID, *P=0.0144
 CTR vs, Tx LOV 6 mg/kg SID, **P=0.0058

Tail Bleeding Time



**CTR vs. GMI 1271 10mg/kg P=0.0063
 **CTR vs. LMWH 6mg/kg P=0.0013
 **GMI 1271 10mg/kg vs. LMWH 6mg/kg P=0.0036

Suman Sood

U.S. Department of Health & Human Services | NIH National Institutes of Health

National Heart, Lung, and Blood Institute

Public | Health Professionals | Researchers | News & Resources | About NHLBI

Home > Researchers > Research Resources > VITA Program

Researchers

FUNDING

TRAINING & CAREER DEVELOPMENT

DIVISION OF INTRAMURAL RESEARCH

RESEARCH RESOURCES

SCIENTIFIC REPORTS

VITA Program

VITA

NHLBI Vascular Interventions/Innovations and Therapeutic Advances (VITA) Program

The Vascular Interventions/Innovations and Therapeutic Advances (VITA) Program is a new translational initiative of the National Heart, Lung, and Blood Institute (NHLBI) that enables and accelerates the development of promising diagnostic and therapeutic modalities for unmet and underserved medical needs. The VITA Program provides contract support for early-stage translational development of product candidates in the fields of vascular disorders, thrombotic diseases, and pulmonary hypertension.

<http://www.nhlbi.nih.gov/research/resources/vita>

Devata S, Angelini DE, Blackburn S, et al. Use of GMI-1271, an E-selectin antagonist, in healthy subjects and in 2 patients with calf vein thrombosis. Res Pract Thromb Haemost 4:193-204, 2020

